Gene · 7468
Papers2,351
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 2,351
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Correction to "Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors". | J Med Chem | 2024 | 39405460 | PubTator, text mining | PubMed |
| Expression of histone methyltransferase WHSC1 in invasive breast cancer and its correlation with clinical and pathological data. | Pathol Res Pract | 2024 | 39395300 | PubTator, text mining | PubMed |
| TGF-β and TNF-α interaction promotes the expression of MMP-9 through H3K36 dimethylation: implications in breast cancer metastasis. | Front Immunol | 2024 | 39351229 | PubTator, text mining | PubMed |
| NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis. | Nat Genet | 2024 | 39251788 | PubTator, text mining | PubMed |
| Dose-dependent effects of histone methyltransferase NSD2 on site-specific double-strand break repair. | Genes Cells | 2024 | 39245559 | PubTator, text mining | PubMed |
| Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2. | J Med Chem | 2024 | 39230932 | PubTator, text mining | PubMed |
Unveiling the potential of phytochemicals to inhibit nuclear receptor binding SET domain protein 2 for cancer: Pharmacophore screening, molecular docking, ADME properties, and molecular dynamics simulation investigations. | PLoS One | 2024 | 39163297 | PubTator, text mining | PubMed |
| Class II ferroptosis inducers are a novel therapeutic approach for t(4;14)-positive multiple myeloma. | Blood Adv | 2024 | 39042883 | PubTator, text mining | PubMed |
| The dual role of NSD2 in mitochondrial function: Insights into interstitial fibrosis and renal cancer. | Pharmacol Res | 2024 | 39032837 | PubTator, text mining | PubMed |
| Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors. | J Med Chem | 2024 | 39008565 | PubTator, text mining | PubMed |
| NSD2-mediated H3K36me2 exacerbates osteoporosis via activation of hoxa2 in bone marrow mesenchymal stem cells. | Cell Signal | 2024 | 38996954 | PubTator, text mining | PubMed |
| Recruitment of FBXO22 for targeted degradation of NSD2. | Nat Chem Biol | 2024 | 38965384 | PubTator, text mining | PubMed |
| Alkylamine-tethered molecules recruit FBXO22 for targeted protein degradation. | Nat Commun | 2024 | 38926334 | PubTator, text mining | PubMed |
| Intestinal NSD2 Aggravates Nonalcoholic Steatohepatitis Through Histone Modifications. | Adv Sci (Weinh) | 2024 | 38923875 | PubTator, text mining | PubMed |
| Downregulation of MMSET Impairs Breast Cancer Proliferation and Metastasis Through Inhibiting Wnt/β-Catenin Signaling [Retraction]. | Onco Targets Ther | 2024 | 38919548 | PubTator, text mining | PubMed |
| Epigenetic modulators provide a path to understanding disease and therapeutic opportunity. | Genes Dev | 2024 | 38914477 | PubTator, text mining | PubMed |
| Multilevel Regulation of NF-κB Signaling by NSD2 Suppresses Kras-Driven Pancreatic Tumorigenesis. | Adv Sci (Weinh) | 2024 | 38889281 | PubTator, text mining | PubMed |
| CD147-K148me2-Driven Tumor Cell-Macrophage Crosstalk Provokes NSCLC Immunosuppression via the CCL5/CCR5 Axis. | Adv Sci (Weinh) | 2024 | 38873823 | PubTator, text mining | PubMed |
| CircWHSC1 (CircNSD2): A Novel Circular RNA in Multiple Cancers. | Clin Med Insights Oncol | 2024 | 38855031 | PubTator, text mining | PubMed |
| Discovery of NSD2 non-histone substrates and design of a super-substrate. | Commun Biol | 2024 | 38851815 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7468/papers?page=7